JPMorgan Chase & Co. increased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1,833.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,536,300 shares of the biopharmaceutical company’s stock after purchasing an additional 1,456,830 shares during the quarter. JPMorgan Chase & Co. owned approximately 1.83% of Catalyst Pharmaceuticals worth $4,240,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. increased its position in Catalyst Pharmaceuticals by 0.5% during the first quarter. Vanguard Group Inc. now owns 3,007,935 shares of the biopharmaceutical company’s stock worth $5,865,000 after buying an additional 15,600 shares during the period. Geode Capital Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 0.3% in the first quarter. Geode Capital Management LLC now owns 462,677 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 1,446 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Catalyst Pharmaceuticals in the first quarter valued at approximately $746,000. Bank of New York Mellon Corp increased its holdings in shares of Catalyst Pharmaceuticals by 206.4% in the second quarter. Bank of New York Mellon Corp now owns 211,979 shares of the biopharmaceutical company’s stock valued at $585,000 after purchasing an additional 142,803 shares during the period. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Catalyst Pharmaceuticals in the second quarter valued at approximately $333,000. Hedge funds and other institutional investors own 40.10% of the company’s stock.
Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) opened at 2.52 on Tuesday. The firm’s market cap is $213.08 million. The stock has a 50 day moving average price of $2.58 and a 200-day moving average price of $2.43. Catalyst Pharmaceuticals, Inc. has a 1-year low of $0.94 and a 1-year high of $3.20.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01. On average, equities research analysts expect that Catalyst Pharmaceuticals, Inc. will post ($0.23) earnings per share for the current fiscal year.
A number of brokerages recently weighed in on CPRX. Zacks Investment Research lowered Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $5.00 target price on shares of Catalyst Pharmaceuticals in a research report on Tuesday, September 5th. Roth Capital set a $5.00 target price on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 10th. Finally, Piper Jaffray Companies set a $6.00 target price on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 7th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $5.50.
In other news, insider Patrick J. Mcenany acquired 20,000 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was acquired at an average price of $2.58 per share, for a total transaction of $51,600.00. Following the transaction, the insider now directly owns 4,471,026 shares in the company, valued at $11,535,247.08. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 8.79% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/markets/jpmorgan-chase-co-grows-position-in-catalyst-pharmaceuticals-inc-cprx/1698004.html.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.